Paris, 21 February 2011 - Neovacs (Alternext Paris: ALNEV), a biotech company focused on an active
immunotherapy technology platform (KinoidsTM) with applications in the treatment of autoimmune
diseases, inflammatory diseases and cancer, today announced that its IFN-K-001 clinical study has
recruited all 28 patients called for by the study protocol and consistent with the Company’s
development plan. Initial results will be the subject of a poster presentation at the 8th European
Lupus Meeting on April 8th in Porto.
The IFN-K-001 study of Neovacs’ IFNa-Kinoid is a double-blind, placebo-controlled trial. It was initiated
in April 2010, with patients recruited in Belgium, Bulgaria, France and Switzerland. Investigator and
patient participation in the study underscores the significant unmet medical need in this disease, and
hence the potential for an innovative therapeutic approach. No new therapy has been approved for
lupus for over 50 years.
The study protocol called for a progressive dose escalation through four dose levels, with each group
randomized between the IFNa-Kinoid and placebo. The principal outcomes to be evaluated from the
study are the safety and tolerability of the Kinoid therapy, the immune response to the Kinoid, the
evolution of disease activity measures and gene signature and chemokine biomarkers. An independent
safety monitoring board reviewed data relating to each dose cohort before approving the
administration of the next dose level to a new cohort.
Initial results relating to the first three dose cohorts will be the subject of a poster presentation on the
8th April 2011 at the 8th European Lupus Meeting which will be held in Porto.
Systemic Lupus Erythematosus (SLE) is an autoimmune disease in which the immune system produces
antibodies to cells within the body leading to widespread inflammation and tissue damage. Prevalence
estimates vary widely, and range as high as 1.5 million in North America (the Lupus Foundation of
America) and 5 million worldwide. The Centers for Disease Control estimates a 2005 prevalence of
322,000 with definite or probable SLE in the US. Lupus disease may first occur at any age, though peak
diagnosis is between the ages of 15 and 40. It is far more common in women than men. People with SLE
may experience fatigue, pain or swelling in joints, skin rashes, and fevers. It can also affect the lungs,
kidneys, and blood vessels. There has been no new treatment approved for lupus for over fifty years.
Scientists have highlighted the overproduction of the interferon alpha cytokine as a key factor in the
causation and development of the disease.
Neovacs is a biotechnology company focused on an active immunotherapy technology platform
(Kinoids™) with applications in autoimmune diseases and other chronic conditions. Neovacs' current
portfolio consists of 3 drug candidates: TNF-Kinoid, IFNa-Kinoid and VEGF-Kinoid. The company’s lead
immunotherapy program (TNF-Kinoid) targets TNF-mediated chronic inflammatory diseases. For TNF-
Kinoid, a Phase I/II clinical trial in Crohn’s disease has been completed and a Phase II trial in rheumatoid
arthritis (RA) is ongoing. The latter clinical study is also the focus of collaboration with the French
diagnostics company BMD, with the goal of developing theranostic tools for personalized care in RA.
Patient recruitment is ongoing in a Phase I/II trial of Neovacs’ second product candidate (IFNa -Kinoid,
an immunotherapy targeting interferon alpha) in the treatment of lupus. Neovacs’ R&D has generated a
broad patent estate.
For more information, visit the Neovacs website at www.neovacs.com
Press - Alize RP
+33 (0) 6 64 18 99 59
lorence Hocdée - Leroy
33 (0) 1 53 10 93 14
Investors – Actifin
3 (0) 1 56 88 11 11